A product leader at a small/medium women’s health biotech company has a background in genomics/genetics, molecular diagnostics, and reproductive health. This stakeholder considers research and investment key unmet needs that lead to a lack of basic biological understanding of women’s health, causing downstream challenges in development of diagnostics, treatments, etc.This stakeholder believes women’s health can benefit from the advances in the prenatal diagnostics space and that success in women’s health will come from aligning incentives with pregnancy/fetal health. They consider unmet needs highest in endometriosis, pregnancy complications, perinatal conditions, contraceptives, and menopause. In the next 1-2 years, they believe perinatal testing, artificial conception, and will see the most precision medicine activity. This stakeholder is excited by activity from Adyn, HeraMED, Delfina, PreFree, Metabolomic Diagnostics, Mirzyme, MOMM Diagnostics, NX Prenatal, and Ovia Health. In the future, they believe major initiatives like the Cancer Moonshot or a specific NIH department from women’s health separate from children could drive growth.

Campaign Details

Precision Medicine Opportunities in Women’s Health Ad Board

DeciBio conducted 11 interviews with OB/GYNs and KOLs in biotech / VC / pharma to explore key unmet needs / challenges, opportunities for precision medicine, and emerging players in women’s health.